Redeye repeats its positive view and Base case of SEK 35 per share following Corline’s report for the second quarter. The report did not include any surprises (which is usually the case with biotech companies), and Corline continues to deliver on our expectations. Over the next months, we are looking forward to getting a more comprehensive insight into the data generated from RENAPAIR 01, as well as news related to the CHS deal with Corline’s North American customer.